role of advanced practitioners in extended endocrine therapy decision-making (or bci)
Published 5 months ago • 23 plays • Length 3:04Download video MP4
Download video MP3
Similar videos
-
0:52
the role of bci in extended endocrine therapy decision making
-
53:42
guideline updates for extended endocrine therapy decision-making in hr , early-stage breast cancer
-
2:26
consideration of side effects in extended endocrine therapy decision making
-
3:22
decision-making impact of the breast cancer index
-
5:04
standardizing extended endocrine therapy recommendations
-
16:19
breast cancer index, extended endocrine therapy | elizabeth ott, pa | 2022 west oncology app updates
-
9:47
bci as a predictive biomarker for extended endocrine therapy benefit
-
4:30
bci: a unique, guideline-recognized test to predict benefit of extended endocrine therapy
-
1:39
utilizing the appropriate tool for extended endocrine therapy decision-making: bci vs oncotype dx
-
1:50
challenges with patient selection for extended adjuvant endocrine therapy in breast cancer
-
1:10:36
updates in extended endocrine therapy for hr breast cancer | asco21 & national practice guidelines
-
10:02
breast cancer: extended adjuvant endocrine therapy
-
1:28
what role do genomic assays play in the decision to extend endocrine therapy?
-
1:13
dr. mamounas on the role of extended adjuvant endocrine therapy in er breast cancer
-
1:23
brock schroeder discusses bci findings in er breast cancer
-
13:04
breast cancer index (bci)
-
3:16
what is breast cancer index?